Outlook Therapeutics
在场
高管
查看带有其 14 名主要高管的组织结构图
Outlook Therapeutics 搜索最多的简介
- Lawrence Kenyon, Chief Executive Officer and Director
- Julian Gangolli, Director
- Randy Thurman, Chairman of the Board
高管在Outlook Therapeutics变化
- Russell Trenary, President, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024十二月4号).
- Lawrence Kenyon 曾任 Chief Financial Officer and Director, 现任 Chief Executive Officer and Director (新闻发布的2024十二月4号).
创建提醒
跟踪 Outlook Therapeutics 的高管变动
生物技术
Outlook Therapeutics 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Outlook Therapeutics 的最新新闻稿
- Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
- Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
- Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
- Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
- Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
- Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
- Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
- Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
- Press Releases - Outlook Therapeutics, Inc.
- Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1 - Outlook Therapeutics, Inc.
- View more press releases Close
通过电子邮件
